## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `article_bundle` — **LLM article bundle** Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. - **article slug:** `pt-141-nsaids` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system. - **read:** https://miscsubjects.com/api/articles/pt-141-nsaids/bundle?format=markdown ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-nsaids/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/pt-141-nsaids/topology - **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/pt-141-nsaids/voxels - **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/pt-141-nsaids/prompts - **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node. - **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/pt-141-nsaids/voxels - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.* --- # miscsubjects article bundle > Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest. ## MASTHEAD - **identity:** `pt-141-nsaids` v2 · content_hash `b649b788808a8179…` · thread_head genesis · 21 DIVs - **thesis (c1):** Two phase 3 RECONNECT trials showed PT-141 improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSDD. - c2 [human/active] No human trials examine PT-141 with NSAIDs or test interactions. - c4 [human/active] PT-141 side effects in trials include nausea (~40%), flushing, and headache with transient BP rise. - c3 [preclinical/active] NSAIDs suppress inflammation signals and may slow tissue repair cascades in preclinical models. - **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes - **standing objections:** 0 open → https://miscsubjects.com/api/articles/pt-141-nsaids/discourse - **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key - **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/pt-141-nsaids/discourse · https://miscsubjects.com/api/protocol ## Article - **slug:** `pt-141-nsaids` - **title:** PT-141 and NSAIDs: Evidence Review for Sexual/CNS Pathways During Anti-Inflammatory Use - **url:** https://miscsubjects.com/a/pt-141-nsaids - **register:** source_ledger - **updated:** 2026-07-17T02:41:08.590Z - **tags:** peptide, matrix ## Body ## What's breaking down if you have NSAIDs NSAID use suppresses key inflammation signals that normally trigger tissue repair cascades. This can slow structural healing in muscles, tendons, joints, and the gut lining. Chronic or repeated dosing trades short-term symptom relief for potential delays in full recovery. In the repair-versus-degeneration frame, the drug reduces the signal load but may let breakdown outpace repair in load-bearing tissues or mucosal barriers. No direct degeneration profile matches the slug, so layers center on suppressed inflammatory resolution and possible secondary effects on sexual function or CNS arousal pathways through systemic stress or discomfort. ## Why PT-141 might help you 1. You are reading about NSAIDs — what breaks down matters before any compound name. 2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. PT-141 acts on melanocortin receptors in the central nervous system to influence sexual desire and arousal pathways. If NSAID-related inflammation or discomfort has layered into reduced sexual interest or CNS signaling fatigue, the compound's studied effect on those specific receptors offers a direct angle on the arousal layer. This sits apart from any anti-inflammatory action; it does not suppress signals the way NSAIDs do. The logic holds only if the sexual or CNS arousal component forms part of the overall picture for the reader. ## Why NSAIDs matters for you Drug: NSAIDs. What it does: Suppress inflammation signal; may slow structural repair cascade. Therefore for you: NSAIDs suppress a signal. This can reduce acute pain and swelling for comfort but trades off against full repair in tissues that rely on controlled inflammation to rebuild. For someone exploring peptides alongside ongoing NSAID use, the suppression may blunt natural repair timelines, making any compound aimed at regeneration pathways worth separate evaluation rather than substitution. ## How these fit together Single-compound focus — PT-141 maps to the sexual / CNS arousal layer. NSAIDs handle symptom suppression via inflammation dampening. The two operate on distinct mechanisms with no documented overlap in the data. PT-141 does not address the inflammatory suppression from NSAIDs, and NSAIDs do not target melanocortin-driven arousal. Any combined use would address separate layers without direct synergy on the same pathway. ## What the evidence actually shows Human trials exist for PT-141 (bremelanotide) in hypoactive sexual desire disorder. Two phase 3 randomized double-blind placebo-controlled studies (RECONNECT) in premenopausal women showed statistically significant gains in sexual desire scores and reductions in related distress versus placebo (source_ids s7). These trials measured desire domain changes on validated scales over 24 weeks. No human trials examine PT-141 in people taking NSAIDs or test any interaction. Preclinical data on PT-141 center on melanocortin receptor activation in animal models of sexual response; rat and other studies demonstrated increased arousal behaviors but do not address NSAID co-administration. NSAID effects on healing come from separate bodies of work, mostly animal models showing delayed tendon or bone repair with certain NSAIDs and observational human data on gastrointestinal and renal impacts. No studies grade the combination. Evidence inventory: multiple human trials for PT-141 sexual effects (tier human); zero human data on the NSAID cross (tier mechanistic/speculative for any inferred link); animal data for each compound separately. ## What scientists say Clinical literature positions PT-141 as a central nervous system modulator for desire without direct hormonal or vascular effects like PDE5 inhibitors. Reviews note consistent side-effect patterns in trials but do not discuss NSAID co-use. NSAID research highlights dose- and duration-dependent impacts on prostaglandin-mediated repair. Experts emphasize separating symptom control from repair support when both are in play. No published commentary addresses the specific pairing. ## What people say on Reddit Reddit threads on PT-141 focus on onset timing, nausea, and libido effects in isolation or with other peptides. No posts link PT-141 directly to NSAID use or report changes in NSAID-related issues. Anecdotes remain general about sexual arousal improvements or side effects (tier anecdotal). ## What people say on X X posts list PT-141 among peptides for libido or contrast it with other compounds like GHK-Cu for anti-inflammatory effects. None mention NSAIDs or any combined use. Discussions stay at the level of individual peptide roles (tier anecdotal). ## What we do not know No data exist on whether PT-141 alters NSAID absorption, efficacy, or side effects. Long-term effects of either compound in combination remain unstudied. Whether CNS arousal changes from PT-141 could indirectly influence pain perception or NSAID reliance is speculative with zero supporting evidence. Human pharmacokinetic interaction studies are absent. ## Safety and limits PT-141 carries documented side effects in human trials, primarily nausea (around 40%), flushing, and headache. Transient blood pressure increases occur. It is contraindicated in uncontrolled hypertension. NSAIDs have their own established profiles including gastrointestinal, cardiovascular, and renal risks with prolonged use. Because no interaction data exist, any concurrent use lacks evidence-based guidance on added risks. All claims here rest on separate compound data; readers should consult primary sources for individual circumstances. ## Claims (4) - **c4** [human w=0.8] PT-141 side effects in trials include nausea (~40%), flushing, and headache with transient BP rise. - who_claims: grok/grok-4.3 - slot: limitations - sources: s9, s10, s11 - **c1** [human w=0.8] Two phase 3 RECONNECT trials showed PT-141 improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSDD. - who_claims: grok/grok-4.3 - sources: s7 - **c2** [human w=0.8] No human trials examine PT-141 with NSAIDs or test interactions. - who_claims: grok/grok-4.3 - **c3** [preclinical w=0.5] NSAIDs suppress inflammation signals and may slow tissue repair cascades in preclinical models. - who_claims: grok/grok-4.3 ## Voxel graph (4 atoms · 8 edges) - full graph: https://miscsubjects.com/api/articles/pt-141-nsaids/voxels ## Article constitution - full: https://miscsubjects.com/api/articles/constitution ## Source ledger (4) - chain valid: yes · head: `fcdafe729951f723` ### s7 · pubmed · ok - title: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder - url: https://journals.lww.com/greenjournal/fulltext/2019/11000/bremelanotide_for_the_treatment_of_hypoactive.2.aspx - summary: Phase 3 RECONNECT trials results on efficacy endpoints. - quote: Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder. - claim_ids: c1 - hash: `c626f41dd011a69c` ### s9 · medical · http_403 - title: Bremelanotide (subcutaneous route) - Side effects & dosage - url: https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805 - summary: Lists common side effects from prescribing information. - quote: Along with its needed effects, a medicine may cause some unwanted effects... More common: Nausea - claim_ids: c4 - hash: `617708b92f326210` ### s10 · pubmed · ok - title: Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder - url: https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/ - summary: Review summarizing trial side effects. - quote: The most common side effects of bremelanotide are nausea, vomiting, and flushing. - claim_ids: c4 - hash: `1dd1a3180a4a73ff` ### s11 · medical · ok - title: PT-141 for Men - url: https://www.towerurology.com/mens-sexual-health/pt-141-for-men/ - summary: Clinical site summarizing trial adverse events. - quote: The most frequently encountered side effect of bremelanotide is nausea (40.0%)... Flushing (20.3%) - claim_ids: c4 - hash: `fcdafe729951f723` ## Provenance (2 model passes) - chain valid: yes · head: `4dde4aad1e6399dd` - write · grok/grok-4.3 · 2026-06-30T01:12 · hash `c40932d0d83e` - voxel_divide · owner · 2026-07-17T02:41 · hash `4dde4aad1e63` ## Question graph - questions: 0 · evidence ingests: 0 ## LLM manifest — how to communicate with this ledger - system map: https://miscsubjects.com/api/articles/system-map?format=markdown - topology (ranked): https://miscsubjects.com/api/articles/pt-141-nsaids/topology - ingest: POST https://miscsubjects.com/api/protocol/ingest - claim: POST https://miscsubjects.com/api/protocol/claim ### Quick actions for this article - **Read live:** https://miscsubjects.com/api/articles/pt-141-nsaids/topology - **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"pt-141-nsaids","question":"..."}` - **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest pt-141-nsaids|your evidence` - **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim pt-141-nsaids|tier|assertion` - **iMessage ask:** `pt-141-nsaids|your question` - **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown --- ## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `system_map` — **System map** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **article slug:** `pt-141-nsaids` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **read:** https://miscsubjects.com/api/articles/system-map ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-nsaids/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest - **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip - **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip - **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/pt-141-nsaids/bundle?format=markdown - **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.*